Abstract: A fault diagnosis method is provided. The method includes: performing a technological process of a diagnostic object to obtain an online operation data sample; extracting a first set of data in a first predetermined period of time from the online operation data sample set as a detecting antigen; calculating deviations of the detecting antigen and all of normal antibodies in a normal antibody database to obtain a first deviation set; determining whether each deviation in the first deviation set is less than a normal antibody threshold; if each deviation in the first deviation set is less than the normal antibody threshold, determining that the technological process is normal, else determining that there is a fault in the technological process.

Abstract: A fault diagnosing method based on a simulated vaccine is provided. The fault diagnosing method comprises steps of: establishing a dynamic simulation model for simulating a start-up operation and a steady-state operation of a technological process according to process information, an operating procedure and historical data of the technological process; running the dynamic simulation model; extracting data within a first predetermined time from the simulated normal sample set to generate a normal simulated vaccine, and extracting data within a second predetermined time from the simulated fault sample set to generate a fault simulated vaccine; acquiring the historical data of the technological process; obtaining an immune antibody coefficient of the normal simulated vaccine, and generating a normal antibody library; and obtaining an immune antibody coefficient of the fault simulated vaccine, and generating a fault antibody library according to the fault simulated vaccine.

Abstract: The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor SCFA2, SCFA4 or SCFA4v polynucleotides and polypeptides. The invention further relates to the therapeutic use of SCFA2, SCFA4 or SCFA4v to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa.

Abstract: The invention relates to the treatment of abnormal or undesirable cell proliferation, particularly endothelial cell proliferation related to tumor growth. The compositions comprise anti-metastatic agents in combination with one or more anti-cancer agent.

Abstract: The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor SCFA2, SCFA4 or SCFA4v polynucleotides and polypeptides. The invention further relates to the therapeutic use of SCFA2, SCFA4 or SCFA4v to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa.

Abstract: The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor SCFA2, SCFA4 or SCFA4v polynucleotides and polypeptides. The invention further relates to the therapeutic use of SCFA2, SCFA4 or SCFA4v to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa.

Abstract: The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor SCFA2, SCFA4 or SCFA4v polynucleotides and polypeptides. The invention further relates to the therapeutic use of SCFA2, SCFA4 or SCFA4v to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa.

Abstract: The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor SCFA2, SCFA4 or SCFA4v polynucleotides and polypeptides. The invention further relates to the therapeutic use of SCFA2, SCFA4 or SCFA4v to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa.

Abstract: An MCM including a resonator made using conventional MCM fabrication techniques. The MCM's resonator is constructed with overlapping first and second spiral-shaped regions of metallic material separated by a layer of dielectric material. A via disposed in the layer of dielectric material, couples the spiral-shaped regions of metallic material together, thereby utilizing self winding and internal capacitance to gain resonance at frequencies between 500 MHz to 3GHz. The internal capacitance is increased by controlling the overlap between the first and second spiral-shaped regions of metallic material. On a high-resistivity substrate, the monolithic resonator achieves a Q of at least 19 at approximately 900MHz and at least 24 at approximately 2GHz.

Abstract: A component design tool extracts a parameter associated with a component defined in a model of a physical system. The design tool discretizes the component and generates a matrix representative of a specified parameter. By subdividing the matrix into a hierarchy of submatrices and iteratively compressing and blending the submatrices, the design tool produces a compressed matrix. The compressed matrix is efficiently solved using iterative techniques. From the solution of the matrix, the design tool calculates the specified parameter.

Abstract: A layered structure is divided into a plurality of regions. Transmission line equivalents (Green's functions) in the spectral domain are formed between all regions within the layered structure. The spectral domain Greens' function are converted to the spatial domain using a near field and a far field computed for those regions part of a component within the layered structure. The far field is extracted from a compressed database computed from the transmission line equivalents and descriptive of the layered structure. The near field is computed using a prioritization mechanism. Priority is assigned in accordance with the amplitude of a source and the length of the path between regions of interest.Once the physical characteristics of the layers used in the fabrication process of the IC are identified, the database used for computation of the far field is compiled and compressed, and remains unchanged for each new parameter extraction.